95 related articles for article (PubMed ID: 25629146)
1. Ivabradine and patients with coronary artery disease: more cardiovascular events.
Prescrire Int; 2014 Dec; 23(155):295. PubMed ID: 25629146
[No Abstract] [Full Text] [Related]
2. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
Fox K; Ferrari R; Tendera M; Steg PG; Ford I;
Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
[TBL] [Abstract][Full Text] [Related]
3. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial.
Fox K; Ford I; Steg PG; Tendera M; Robertson M; Ferrari R;
Eur Heart J; 2009 Oct; 30(19):2337-45. PubMed ID: 19720635
[TBL] [Abstract][Full Text] [Related]
4. Ivabradine: more precautions to protect patients with coronary artery disease because of its cardiac harms.
Prescrire Int; 2015 Nov; 24(165):264. PubMed ID: 26688895
[TBL] [Abstract][Full Text] [Related]
5. Heart failure: ivabradine is no better than optimised beta-blocker therapy.
Prescrire Int; 2011; 20(118):189-90. PubMed ID: 21751757
[TBL] [Abstract][Full Text] [Related]
6. Safety of ivabradine in patients with coronary artery disease and left ventricular systolic dysfunction (from the BEAUTIFUL Holter Substudy).
Tendera M; Talajic M; Robertson M; Tardif JC; Ferrari R; Ford I; Steg PG; Fox K;
Am J Cardiol; 2011 Mar; 107(6):805-11. PubMed ID: 21247517
[TBL] [Abstract][Full Text] [Related]
7. Heart rate-lowering efficacy and respiratory safety of ivabradine in patients with obstructive airway disease: a randomized, double-blind, placebo-controlled, crossover study.
Majewski S; Slomka S; Zielinska-Wyderkiewicz E; Ciebiada M; Gorski P
Am J Cardiovasc Drugs; 2012 Jun; 12(3):179-88. PubMed ID: 22409211
[TBL] [Abstract][Full Text] [Related]
8. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
Canet E; Lerebours G; Vilaine JP
Ann N Y Acad Sci; 2011 Mar; 1222():90-9. PubMed ID: 21434947
[TBL] [Abstract][Full Text] [Related]
9. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
Bruguera Cortada J; Varela A
Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
[TBL] [Abstract][Full Text] [Related]
10. Ivabradine: from molecular basis to clinical effectiveness.
Riccioni G
Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
[TBL] [Abstract][Full Text] [Related]
11. Impact of a pure reduction in heart rate for the treatment of left ventricular dysfunction: clinical benefits of ivabradine in the BEAUTIFUL trial.
Danchin N
Therapie; 2009; 64(2):111-4. PubMed ID: 19664404
[TBL] [Abstract][Full Text] [Related]
12. Selective and specific I(f) inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease.
Ferrari R; Ceconi C
Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):959-73. PubMed ID: 21878041
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of ivabradine in patients with chronic stable angina.
López-Bescós L; Filipova S; Martos R
Cardiology; 2007; 108(4):387-96. PubMed ID: 17890862
[TBL] [Abstract][Full Text] [Related]
14. Impact of left bundle branch block on heart rate and its relationship to treatment with ivabradine in chronic heart failure.
Reil JC; Robertson M; Ford I; Borer J; Komajda M; Swedberg K; Tavazzi L; Böhm M
Eur J Heart Fail; 2013 Sep; 15(9):1044-52. PubMed ID: 23696612
[TBL] [Abstract][Full Text] [Related]
15. Ivabradine: beyond heart rate control.
Riccioni G; Vitulano N; D'Orazio N
Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
[TBL] [Abstract][Full Text] [Related]
16. Rate control with ivabradine: angina pectoris and beyond.
Parakh N; Bhargava B
Am J Cardiovasc Drugs; 2011; 11(1):1-12. PubMed ID: 21090826
[TBL] [Abstract][Full Text] [Related]
17. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
Rosano GM; Vitale C; Volterrani M
Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
[TBL] [Abstract][Full Text] [Related]
18. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
Perry CM
Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
[TBL] [Abstract][Full Text] [Related]
19. Ivabradine: new drug. Best avoided in stable angina.
Prescrire Int; 2007 Apr; 16(88):53-6. PubMed ID: 17458043
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of ivabradine, a selective I(f) inhibitor, in patients with chronic stable angina pectoris and diabetes mellitus.
Borer JS; Tardif JC
Am J Cardiol; 2010 Jan; 105(1):29-35. PubMed ID: 20102886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
